(Reprint) Xinhua News Agency: Kangtai Biological and Chile Sign a Cooperation Agreement for Phase III Clinical Trials of a COVID-19 Vaccine

Release date:

2021-05-25

Author:

Source:


Abstract

SANTIAGO, May 24 (Xinhua) — By reporter Zhang Xiaoran: On the 24th, Chile’s Advanced Medical Systems Investment Company, the University of Chile, and other institutions held a virtual signing ceremony with China’s Shenzhen Kangtai Biological Products Co., Ltd. (hereinafter referred to as “Kangtai Bio”), reaching an agreement on conducting Phase III clinical trials of Kangtai Bio’s inactivated COVID‑19 vaccine in Chile and on the procurement of its products. Attending the signing ceremony were Chile’s Special Envoy for Asia-Pacific Affairs and former President Ricardo Lagos, Chilean Vice Minister of Foreign Affairs José Miguel Yáñez, as well as representatives from the Chinese Embassy in Chile, the Chilean Embassy in China, and other relevant organizations. At the ceremony, Kangtai Bio stated that it hopes this collaboration will both advance Kangtai Bio’s new…

SANTIAGO, May 24 (Xinhua) — By reporter Zhang Xiaoran: On the 24th, Chile’s Advanced Medical Systems Investment Company, the University of Chile, and other institutions held a virtual signing ceremony with China’s Shenzhen Kangtai Biological Products Co., Ltd. (referred to as “Kangtai Bio”), reaching an agreement on conducting Phase III clinical trials of Kangtai Bio’s inactivated COVID‑19 vaccine in Chile and on the procurement of its products.

  Chile’s Special Envoy for Asia-Pacific Affairs and former President Frei, Chilean Vice Minister of Foreign Affairs Yáñez, along with representatives from the Chinese Embassy in Chile, the Chilean Embassy in China, and other institutions, attended the signing ceremony.

  At the signing ceremony, Kangtai Biological stated that it hopes this collaboration will both advance the Phase III clinical trials of its COVID‑19 vaccine and support its supply as a public good worldwide, particularly in developing countries, while also establishing an international model for industry–university–research cooperation in the field of vaccine development.

  On the 14th, Kangtai Biological announced that its COVID-19 vaccine has been approved for emergency use in China. At present, Kangtai Biological has initiated Phase III clinical trials of its COVID-19 vaccine in multiple countries worldwide.

Recommended Reading


Batch Release Status of the Company’s Products in 2026


The company's product 2026 annual batch issuance situation is as follows:

2026-07-23

Good News | Another Star Award! Minhai Biotechnology has once again been recognized as a “Five-Star Green Credit Enterprise” in Daxing District.


Recently, the Daxing District Bureau of Ecology and Environment completed the fifth round of corporate green credit rating for 2025 and officially released the “2025 Daxing District Green Credit Enterprise Directory.” Thanks to its robust environmental management system, consistent compliance performance, and outstanding achievements in energy conservation and carbon reduction, Minhai Biotechnology has once again been awarded the region’s highest “Five-Star Green Credit Enterprise” rating. The Daxing District’s corporate green credit assessment covers five major categories—environmental compliance, pollution control and emission reduction, low‑carbon circular economy, scientific management, and social contribution—comprising a total of 30 sub‑indicators. With stringent standards and comprehensive evaluation, the program employs dynamic review and a veto‑based mechanism, with the Five‑Star rating representing the highest level of ecological credit in the district.

2026-07-15

Good News | The Party Branch of Minhai Biotechnology has been awarded the “Two Excellences and One Pioneer” honor in Beijing’s emerging sectors, as well as a park‑level commendation.


Recently, Beijing held a grand commendation conference for the “Two Excellences and One Pioneer” initiative in emerging sectors. The “Two New” Working Committee of the CPC Beijing Municipal Committee recognized outstanding Communist Party members, exemplary Party affairs workers, and advanced primary-level Party organizations across the city’s emerging fields. The Party branch of Beijing Minhai Biotechnology Co., Ltd. was honored as an advanced primary-level Party organization in Beijing’s emerging sectors. Wu Chengyu, the branch secretary, attended the ceremony in person to receive the award. At the event, the Party flag flew proudly amid a solemn atmosphere, and the awardees, adorned with honor ribbons and holding certificates and medals, jointly witnessed this prestigious municipal recognition. This designation as an advanced primary-level Party organization at the municipal level represents the “Two New” Working Committee of the Municipal Party Committee’s high appraisal of the Minhai Biotechnology Party branch.

2026-07-09